Drug combination after surgery for early cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests a combination of two drugs (camrelizumab and famitinib) given after surgery for early-stage cervical cancer. The goal is to see if this treatment helps keep the cancer from returning. It is for people who have not had any other cancer treatment yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 75 years.
- You have had surgery to remove the cancer and have not yet had any other cancer treatment (like chemotherapy or radiation).
- Your tumor tests positive for a protein called PD-L1 (this is usually checked on a sample from your surgery).
- You have one of these types of cervical cancer: squamous cell, adenosquamous, or adenocarcinoma.
- Your cancer is at an early stage (IA, IB1, IB2, IIA1, IB3, or IIA2).
- You are in good overall health (able to care for yourself, with normal heart, liver, kidney, and blood function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—camrelizumab (an immunotherapy that helps your immune system fight cancer), famitinib (a targeted therapy that blocks blood vessel growth to tumors), and standard chemotherapy—for cervical cancer that has come back or spread and cannot be removed with surgery or radiation. The goal is to see if this combination is safe and effective.
This trial tests whether giving chemotherapy combined with camrelizumab (a drug that helps the immune system fight cancer) before surgery can help women with early-stage cervical cancer who want to preserve their fertility. It is for patients whose tumors show a protein called PD-L1.
This trial tests whether combining chemotherapy with immunotherapy before surgery can help treat cervical cancer that is PD-L1 negative. It's for women with larger tumors (stage IB3 to IIB) who have not been treated yet.
This trial tests whether a combination of chemotherapy and immunotherapy (pembrolizumab) before surgery works better than standard chemoradiation for locally advanced cervical cancer. It may help shrink tumors more effectively.
This trial tests if giving chemotherapy plus an immunotherapy drug before surgery can help shrink tumors and improve outcomes for patients with stage IB2 cervical cancer that has not been treated yet. It might be an option if you have a specific type of cervical cancer that shows a certain protein (PD-L1) on your tumor cells.
This trial tests a combination of two drugs: an antibody-drug conjugate (RC48-ADC) that targets HER2 on cancer cells, plus an immunotherapy (Zimberelimab) that helps your immune system attack the cancer. It is for people with advanced cervical cancer whose prior platinum-based chemotherapy has stopped working.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.